Matritech (Newton, Massachusetts), a developer of protein-based diagnostic products for the early detection of cancer, said it has filed a plan with the American Stock Exchange (AMEX) outlining the actions it proposes to take to bring it into compliance no later than March 21, 2008, with AMEX's listing standards.

Matritech previously reported it had been informed that it was not in compliance with AMEX's continued listing standards but was allowed to submit a compliance plan by Oct. 23.

If AMEX accepts the plan, the company may be able to continue its listing for up to 18 months, during which time it will undergo periodic review concerning progress. If there is no progress, AMEX can initiate delisting proceedings.

Millipore opens $50 million R&D Center

Millipore (Billerica, Massachusetts) has opened a new $50 million research and development center in Bedford, Massachusetts.

The 110,000 square foot building contains 47,000 square feet of lab space, and consolidates multiple functions for 500 employees who will work there.

Martin Madaus, CEO and chairman of Millipore, said the center enables the company "to attract scientific talent and bring together multiple research disciplines to develop integrated solutions. These solutions will create value for our biotechnology and pharmaceutical customers and fuel our continued growth as a leader in the life sciences industry."

Millipore is a provider of products and services designed to improve productivity in biopharmaceutical manufacturing and in clinical, analytical and research laboratories.